Navigation Links
'Watch and Wait' Approach Often Best for Older Patients With Kidney Cancer
Date:2/12/2013

TUESDAY, Feb. 12 (HealthDay News) -- Sometimes, simply watching and waiting is a safe alternative to surgery for older patients with small kidney tumors, a new study suggests.

"Physicians can comfortably tell an elderly patient, especially a patient that is not healthy enough to tolerate general anesthesia and surgery, that the likelihood of dying of kidney cancer is low and that kidney surgery is unlikely to extend their lives," study lead author Dr. William Huang, an assistant professor of urologic oncology at NYU Medical Center, said in a news release from the American Society of Clinical Oncology (ASCO).

The findings are to be presented Saturday at an ASCO conference in New York City. Research presented at medical meetings is typically considered preliminary until published in a peer-reviewed journal.

In their study, Huang's team analyzed data from more than 8,300 patients aged 66 and older who were diagnosed with small kidney tumors (less than 1.5 inches in diameter). Of those patients, 70 percent had surgery to remove either a part of the kidney or the entire organ and 31 percent underwent surveillance with imaging such as MRI, ultrasound and CT.

Over nearly five years of follow-up, 25 percent of the patients died from all causes and three percent of the patients died of kidney cancer. The rates of kidney cancer death were the same for patients who had surgery and those who underwent surveillance.

However, the study found patients in the surveillance group had a much lower risk of death from any cause, as well as a lower risk of having cardiovascular problems such as heart failure, stroke or vascular disease.

Huang stressed, however, that some patients may still prefer a surgical approach. "Since it is difficult to identify which tumors will become lethal, elderly patients who are completely healthy and have an extended life expectancy, may opt for surgery," he explained.

The researchers also found that the percentage of patients with small kidney tumors who were managed with surveillance increased between 25 percent to 37 percent from 2000 to 2007. This suggests that doctors are becoming more aware that small kidney tumors may not pose a threat, even if they are cancerous, the study authors said.

Two experts working with kidney cancer patients agreed that a "watch and wait" approach may be suitable for some patients.

The study "reaffirms the growing understanding that small [kidney] masses are relatively slow growing and generally pose only a small risk especially in the elderly population," said Dr. Manish Vira, director of the fellowship program in urologic oncology at North Shore LIJ's Arthur Smith Institute for Urology, in Lake Success, N.Y.

However, he noted that "although the risk is small, it is not zero as demonstrated by the finding that 3 percent [of the patients in the study] died of kidney cancer."

"It would interesting to look at these patients to determine if there are specific risk factors that predict more aggressive behavior of these small masses," Vira said. "This would allow physicians to target treatment for those patients with small [kidney] masses who are at higher risk."

Dr. Matthew Galsky is director of genitourinary medical oncology at the Tisch Cancer Institute at Mount Sinai School of Medicine, in New York City. He said prior studies "have shown that small kidney tumors that are not removed grow relatively slowly (approximately 0.3-0.4 centimeters per year) and in one series, only 1 percent of such tumors spread to other places in the body."

Galsky said the new study did have some limitations -- it was retrospective, looking over past data rather than the "gold standard" prospective form of trial -- and the methods of surveillance (such as scans) for the patients who did not get surgery was not made clear.

Nevertheless, he said, the findings, "should allow clinicians and patients to feel more comfortable about surveillance, particularly for the 'oldest old' and those patients with multiple [other health conditions] that would make surgery especially high risk."

More information

The National Kidney Foundation has more about kidney cancer.

-- Robert Preidt

SOURCES: Matthew D. Galsky, M.D., director, genitourinary medical oncology and associate professor of medicine, Tisch Cancer Institute, Mount Sinai School of Medicine, New York City; Manish A. Vira, M.D.; director, fellowship program in urologic oncology, North Shore LIJ's the Arthur Smith Institute for Urology, Lake Success, N.Y.; American Society of Clinical Oncology, news release, Feb. 12, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. US Drug Watchdog Now Urges All Recalled DePuy ASR Hip Implant Recipients Call Them For The Names Of The Best Attorneys Out Of Fear The Recipients Will Get Nothing
2. US Drug Watchdog Launches Now Calls Transvaginal Mesh A Disaster For 100,000's of US Women Recipients And Offers The Names and Contacts Of The Best Women Attorneys
3. US Drug Watchdog Now Offers To Get A Free Legal Review For All DePuy ASR Recipients Who Received A Letter From Broadspire About Their Recalled DePuy Hip Implant
4. US Drug Watchdog Now Offers To Help All Recipients Of A DePuy Pinnacle Or Recalled DePuy ASR Hip Implant Get To The Best Attorneys Regardless If Their Device Has Failed
5. US Drug Watchdog Now Urges All DePuy Pinnacle Hip Implant Recipients To Know The Symptoms Of A Failure And Offers To Name The Best Lawyers & Law Firms For Failure Victims
6. US Drug Watchdog Now Offers To Help Every Recipient Of A DePuy Pinnacle Or Recalled DePuy ASR Hip Implant Who Had To Go Through Revision Surgery Get To The Best Lawyers
7. Polar RCX5 Tour de France Available At The Heart Rate Watch Company
8. US Drug Watchdog Dramatically Increases Their Efforts To Get All Recalled DePuy ASR Hip Implant Recipients Identified To The Best Possible Attorneys Before Time Runs Out
9. US Drug Watchdog Now Offers To Help Women Who Used TheOsteoporosis Drug Called Fosamax And Then Had A Unexplainable Femur Fracture Get To The Best Attorneys Or Law Firms
10. The US Drug Watchdog Now Offers Women Who Had A Heart Attack Or Stroke After Using The Birth Control Pills Yaz Yasmin Birth Control Pills Get To The Best Attorneys
11. The US Drug Watchdog Now Urges Plaintiffs Law Firms Worldwide To Contact Them About A Possible International Effort To Help Victims Of Defective Drugs Or Medical Devices
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Watch and Wait' Approach Often Best for Older Patients With Kidney Cancer
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: